Abstract Background and Objective Rivaroxaban is a novel oral anticoagulant widely used
for thromboprophylaxis in patients with non-valvular atrial fibrillation (NVAF). The present …

Rivaroxaban is a direct‐acting oral anticoagulant approved to prevent strokes in patients
with atrial fibrillation. Dosage recommendations are approved for all adult patients to receive …

Purpose Low-dose rivaroxaban is often given to patients with atrial fibrillation (AF) around
the world, but the rationale for its use remains unclear. We aimed to compare the efficacy …

Background: It is important to understand the risk of thromboembolism and bleeding in
patients with nonvalvular atrial fibrillation (NVAF) receiving direct oral anticoagulants; …

Background: Practice-based investigations on direct oral anticoagulant (DOAC) treatment for
non-valvular atrial fibrillation (NVAF) have shown that off-label under-dosing is increasingly …

Purpose 10 mg rivaroxaban is widely used in the Chinese mainland. This study aims to
explore the association between 10 mg once daily rivaroxaban and all-cause mortality in …

Rivaroxaban is a direct factor Xa inhibitor that is widely available to reduce the risk of stroke
or systemic embolism in patients with nonvalvular atrial fibrillation and one or more risk …

Aims Although non-vitamin K antagonist oral anticoagulants are recommended for stroke
prevention in patients with non-valvular atrial fibrillation (NVAF) based on clinical trial …

Background Real-world evidence on factor Xa inhibitor (rivaroxaban) prescribing patterns,
safety, and efficacy in patients with non-valvular atrial fibrillation (NVAF) and venous …

Background Results from the J-ROCKET AF study revealed that rivaroxaban was non-
inferior to warfarin with respect to the principal safety outcomes in patients with non-valvular …